<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Dallas Retatrutide - Triple Agonist Weight Loss | Summer House</title>
    <meta name="description" content="Discover retatrutide in Dallas - the next-generation triple agonist weight loss medication with 24-26% clinical results. Learn how it compares to semaglutide and tirzepatide.">
    <meta name="keywords" content="Dallas retatrutide, weight loss Dallas, triple agonist medication, GLP-1 GIP glucagon agonist">
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Roboto', 'Oxygen', 'Ubuntu', 'Cantarell', sans-serif;
            line-height: 1.6;
            color: #333;
            background-color: #faf9f7;
        }

        /* Summer House Brand Colors */
        .brand-green: #2d5a3d;
        .brand-cream: #f5f3f0;
        .brand-light-green: #e8ede6;

        header {
            background: linear-gradient(135deg, #2d5a3d 0%, #3a6f48 100%);
            color: white;
            padding: 20px 0;
            box-shadow: 0 2px 8px rgba(0,0,0,0.1);
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 0 20px;
        }

        .header-content {
            display: flex;
            justify-content: space-between;
            align-items: center;
            padding: 15px 0;
        }

        .logo {
            font-size: 24px;
            font-weight: 700;
            letter-spacing: -0.5px;
        }

        nav a {
            color: white;
            text-decoration: none;
            margin-left: 30px;
            font-size: 14px;
            transition: opacity 0.3s;
        }

        nav a:hover {
            opacity: 0.8;
        }

        /* Hero Section */
        .hero {
            background: linear-gradient(135deg, #2d5a3d 0%, #3a6f48 100%);
            color: white;
            padding: 80px 0;
            text-align: center;
        }

        .hero h1 {
            font-size: 48px;
            margin-bottom: 20px;
            line-height: 1.2;
            font-weight: 700;
        }

        .hero p {
            font-size: 20px;
            margin-bottom: 30px;
            opacity: 0.95;
            max-width: 600px;
            margin-left: auto;
            margin-right: auto;
        }

        .cta-button {
            display: inline-block;
            background-color: #fff;
            color: #2d5a3d;
            padding: 14px 32px;
            border-radius: 6px;
            text-decoration: none;
            font-weight: 600;
            font-size: 16px;
            transition: all 0.3s;
            border: 2px solid white;
            cursor: pointer;
            margin: 10px;
        }

        .cta-button:hover {
            background-color: #e8ede6;
            transform: translateY(-2px);
            box-shadow: 0 8px 16px rgba(0,0,0,0.2);
        }

        .cta-button-secondary {
            display: inline-block;
            background-color: transparent;
            color: white;
            padding: 14px 32px;
            border-radius: 6px;
            text-decoration: none;
            font-weight: 600;
            font-size: 16px;
            transition: all 0.3s;
            border: 2px solid white;
            cursor: pointer;
            margin: 10px;
        }

        .cta-button-secondary:hover {
            background-color: rgba(255,255,255,0.1);
            transform: translateY(-2px);
        }

        /* Content Sections */
        .section {
            padding: 60px 0;
            background-color: white;
            border-bottom: 1px solid #f0f0f0;
        }

        .section:nth-child(even) {
            background-color: #faf9f7;
        }

        .section h2 {
            font-size: 36px;
            margin-bottom: 30px;
            color: #2d5a3d;
            text-align: center;
        }

        .section h3 {
            font-size: 22px;
            margin-bottom: 15px;
            color: #2d5a3d;
            margin-top: 25px;
        }

        .two-column {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 40px;
            margin-bottom: 40px;
        }

        .feature-box {
            background: white;
            padding: 30px;
            border-radius: 8px;
            border-left: 4px solid #2d5a3d;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        .feature-box h4 {
            color: #2d5a3d;
            margin-bottom: 12px;
            font-size: 18px;
        }

        /* Comparison Table */
        .comparison-table {
            width: 100%;
            border-collapse: collapse;
            margin: 40px 0;
            background: white;
            border-radius: 8px;
            overflow: hidden;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        .comparison-table th {
            background-color: #2d5a3d;
            color: white;
            padding: 16px;
            text-align: left;
            font-weight: 600;
        }

        .comparison-table td {
            padding: 14px 16px;
            border-bottom: 1px solid #e8ede6;
        }

        .comparison-table tr:last-child td {
            border-bottom: none;
        }

        .comparison-table tbody tr:hover {
            background-color: #f5f3f0;
        }

        .status-approved {
            color: #27ae60;
            font-weight: 600;
        }

        .status-trial {
            color: #e67e22;
            font-weight: 600;
        }

        /* FAQ Section */
        .faq-item {
            margin-bottom: 20px;
            border: 1px solid #e8ede6;
            border-radius: 6px;
            overflow: hidden;
        }

        .faq-question {
            background-color: #e8ede6;
            padding: 18px;
            cursor: pointer;
            font-weight: 600;
            color: #2d5a3d;
            transition: all 0.3s;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        .faq-question:hover {
            background-color: #dce4d8;
        }

        .faq-answer {
            padding: 18px;
            background: white;
            display: none;
            line-height: 1.7;
        }

        .faq-item.active .faq-answer {
            display: block;
        }

        .faq-toggle {
            font-size: 20px;
            transition: transform 0.3s;
        }

        .faq-item.active .faq-toggle {
            transform: rotate(180deg);
        }

        /* Waitlist Form */
        .waitlist-form {
            background: white;
            padding: 40px;
            border-radius: 8px;
            max-width: 500px;
            margin: 40px auto;
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            border: 1px solid #e8ede6;
        }

        .form-group {
            margin-bottom: 20px;
        }

        .form-group label {
            display: block;
            margin-bottom: 8px;
            font-weight: 600;
            color: #2d5a3d;
        }

        .form-group input {
            width: 100%;
            padding: 12px;
            border: 1px solid #ddd;
            border-radius: 6px;
            font-size: 14px;
            transition: border-color 0.3s;
        }

        .form-group input:focus {
            outline: none;
            border-color: #2d5a3d;
            box-shadow: 0 0 0 3px rgba(45, 90, 61, 0.1);
        }

        .form-submit {
            width: 100%;
            padding: 14px;
            background-color: #2d5a3d;
            color: white;
            border: none;
            border-radius: 6px;
            font-weight: 600;
            font-size: 16px;
            cursor: pointer;
            transition: all 0.3s;
        }

        .form-submit:hover {
            background-color: #1f3d27;
            transform: translateY(-2px);
            box-shadow: 0 4px 12px rgba(45, 90, 61, 0.3);
        }

        /* Footer */
        footer {
            background-color: #2d5a3d;
            color: white;
            padding: 40px 0;
            text-align: center;
            font-size: 14px;
        }

        footer p {
            margin-bottom: 10px;
        }

        footer a {
            color: #e8ede6;
            text-decoration: none;
        }

        footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .hero h1 {
                font-size: 32px;
            }

            .hero p {
                font-size: 16px;
            }

            .two-column {
                grid-template-columns: 1fr;
            }

            .section h2 {
                font-size: 28px;
            }

            nav {
                display: none;
            }
        }

        .highlight {
            color: #2d5a3d;
            font-weight: 600;
        }

        .trial-badge {
            display: inline-block;
            background-color: #fff3cd;
            color: #856404;
            padding: 6px 12px;
            border-radius: 4px;
            font-size: 12px;
            font-weight: 600;
            margin-bottom: 20px;
        }

        .benefits-grid {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 20px;
            margin: 30px 0;
        }

        .benefit-item {
            background: #f5f3f0;
            padding: 20px;
            border-radius: 6px;
            border-left: 4px solid #2d5a3d;
        }

        .benefit-item h4 {
            color: #2d5a3d;
            margin-bottom: 8px;
            font-size: 16px;
        }

        @media (max-width: 768px) {
            .benefits-grid {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>
<body>
    <header>
        <div class="container">
            <div class="header-content">
                <div class="logo">Summer House Aesthetics</div>
                <nav>
                    <a href="#mechanism">How It Works</a>
                    <a href="#comparison">Comparison</a>
                    <a href="#timeline">Availability</a>
                    <a href="#faq">FAQ</a>
                </nav>
            </div>
        </div>
    </header>

    <section class="hero">
        <div class="container">
            <h1>Dallas Retatrutide</h1>
            <p>The Triple Agonist Breakthrough — 24-26% Weight Loss in Clinical Trials Comes to Dallas</p>
            <a href="#waitlist" class="cta-button">Get on the Waitlist</a>
            <a href="#current-options" class="cta-button-secondary">Start Weight Loss Today</a>
        </div>
    </section>

    <section class="section" id="mechanism">
        <div class="container">
            <h2>The Triple Agonist Advantage</h2>

            <p style="text-align: center; margin-bottom: 30px; font-size: 16px; max-width: 800px; margin-left: auto; margin-right: auto;">
                Retatrutide isn't just another weight loss medication. It works through three separate metabolic pathways simultaneously, delivering superior results.
            </p>

            <div class="benefits-grid">
                <div class="benefit-item">
                    <h4>GLP-1 Receptor</h4>
                    <p>Reduces appetite and increases satiety. You feel fuller longer and eat less.</p>
                </div>
                <div class="benefit-item">
                    <h4>GIP Receptor</h4>
                    <p>Enhances insulin sensitivity and improves blood sugar control for better metabolism.</p>
                </div>
                <div class="benefit-item">
                    <h4>Glucagon Receptor</h4>
                    <p>Increases energy expenditure and fat burning. Your body burns more calories at rest.</p>
                </div>
                <div class="benefit-item">
                    <h4>Triple Action Result</h4>
                    <p>Combined effect produces superior weight loss compared to single or dual agonists.</p>
                </div>
            </div>

            <div style="background: #f5f3f0; padding: 30px; border-radius: 8px; margin-top: 30px;">
                <h3 style="text-align: center; margin-bottom: 20px;">Why Three Mechanisms Beat Two (or One)</h3>
                <p style="margin-bottom: 15px;">Traditional weight loss medications work through one or two pathways. Retatrutide's triple approach addresses weight loss comprehensively:</p>
                <ul style="padding-left: 20px; margin-bottom: 15px;">
                    <li style="margin-bottom: 10px;"><strong>Appetite suppression +</strong> metabolism enhancement + insulin control</li>
                    <li style="margin-bottom: 10px;">More targets = more effective weight loss mechanisms</li>
                    <li style="margin-bottom: 10px;">Better sustained results throughout treatment</li>
                    <li>Improved overall metabolic health, not just weight loss</li>
                </ul>
                <p style="margin-top: 15px; font-size: 14px; color: #666; font-style: italic;">This is why retatrutide shows 24-26% weight loss vs 20-22% for tirzepatide (GLP-1/GIP dual) and 15-18% for semaglutide (GLP-1 only).</p>
            </div>
        </div>
    </section>

    <section class="section">
        <div class="container">
            <h2>Real Clinical Trial Results</h2>

            <div class="trial-badge" style="display: block; text-align: center; width: fit-content; margin: 0 auto 30px;">Phase 3 SURMOUNT Clinical Trials</div>

            <div class="two-column">
                <div class="feature-box">
                    <h4>Retatrutide (Phase 3)</h4>
                    <p style="font-size: 28px; color: #2d5a3d; margin: 15px 0; font-weight: 700;">24-26%</p>
                    <p style="color: #666; margin-bottom: 15px;">Average weight loss in 48-week clinical trials</p>
                    <p style="font-size: 14px; color: #999;">Source: Eli Lilly Clinical Data - SURMOUNT Trials</p>
                </div>

                <div class="feature-box">
                    <h4>Why This Matters</h4>
                    <p style="margin-bottom: 12px;"><strong>8% better than tirzepatide</strong> (20-22%)</p>
                    <p style="margin-bottom: 12px;"><strong>9% better than semaglutide</strong> (15-18%)</p>
                    <p style="margin-top: 15px; padding-top: 15px; border-top: 1px solid #e8ede6;">For a 200 lb person, that's 36+ lbs vs 30 lbs with current options.</p>
                </div>
            </div>

            <h3 style="text-align: center; margin-top: 40px; margin-bottom: 25px;">Key Trial Outcomes</h3>
            <div style="background: white; border: 1px solid #e8ede6; border-radius: 8px; overflow: hidden;">
                <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 0;">
                    <div style="padding: 25px; border-right: 1px solid #e8ede6; border-bottom: 1px solid #e8ede6;">
                        <h4 style="color: #2d5a3d; margin-bottom: 10px;">Weight Loss Durability</h4>
                        <p style="font-size: 14px;">Weight loss sustained throughout 48-week study period with consistent results.</p>
                    </div>
                    <div style="padding: 25px; border-right: 1px solid #e8ede6; border-bottom: 1px solid #e8ede6;">
                        <h4 style="color: #2d5a3d; margin-bottom: 10px;">Safety Profile</h4>
                        <p style="font-size: 14px;">Well-tolerated with side effect profile similar to other GLP-1 class drugs.</p>
                    </div>
                    <div style="padding: 25px; border-bottom: 1px solid #e8ede6;">
                        <h4 style="color: #2d5a3d; margin-bottom: 10px;">Metabolic Benefits</h4>
                        <p style="font-size: 14px;">Improved insulin sensitivity and blood sugar control beyond weight loss.</p>
                    </div>
                    <div style="padding: 25px;">
                        <h4 style="color: #2d5a3d; margin-bottom: 10px;">Cardiovascular Health</h4>
                        <p style="font-size: 14px;">Positive effects on blood pressure, cholesterol, and heart health markers.</p>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <section class="section" id="comparison">
        <div class="container">
            <h2>How Retatrutide Compares</h2>

            <p style="text-align: center; margin-bottom: 30px; color: #666;">
                Here's how the latest weight loss medications stack up against each other:
            </p>

            <table class="comparison-table">
                <thead>
                    <tr>
                        <th>Medication</th>
                        <th>Type / Mechanism</th>
                        <th>Average Weight Loss</th>
                        <th>FDA Status</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Semaglutide</strong> (Ozempic, Wegovy)</td>
                        <td>GLP-1 Agonist (1 pathway)</td>
                        <td>15-18%</td>
                        <td><span class="status-approved">FDA Approved</span></td>
                    </tr>
                    <tr>
                        <td><strong>Tirzepatide</strong> (Mounjaro, Zepbound)</td>
                        <td>GLP-1/GIP (2 pathways)</td>
                        <td>20-22%</td>
                        <td><span class="status-approved">FDA Approved</span></td>
                    </tr>
                    <tr style="background-color: #f0f8f4;">
                        <td><strong>Retatrutide</strong></td>
                        <td>GLP-1/GIP/Glucagon (3 pathways)</td>
                        <td><strong>24-26%</strong></td>
                        <td><span class="status-trial">Phase 3 Trials</span></td>
                    </tr>
                </tbody>
            </table>

            <div style="background: #f5f3f0; padding: 25px; border-radius: 8px; margin-top: 25px;">
                <h4 style="color: #2d5a3d; margin-bottom: 12px;">The Triple Agonist Difference</h4>
                <p>More agonist pathways = better weight loss outcomes. Retatrutide adds a third pathway (glucagon) that earlier medications don't have, resulting in measurably superior results in clinical trials.</p>
            </div>
        </div>
    </section>

    <section class="section" id="timeline">
        <div class="container">
            <h2>When Will Retatrutide Be Available in Dallas?</h2>

            <div class="two-column">
                <div class="feature-box">
                    <h4>FDA Approval Timeline</h4>
                    <div style="background: #2d5a3d; color: white; padding: 20px; border-radius: 6px; text-align: center; margin: 15px 0;">
                        <p style="font-size: 28px; font-weight: 700; margin-bottom: 5px;">2025-2026</p>
                        <p style="font-size: 14px;">Expected FDA approval window</p>
                    </div>
                    <p style="font-size: 14px; color: #666; margin-top: 15px;">Timeline based on Phase 3 trial progress and typical FDA review processes.</p>
                </div>

                <div class="feature-box">
                    <h4>Summer House Launch Plan</h4>
                    <ul style="margin: 15px 0; padding-left: 20px;">
                        <li style="margin-bottom: 10px;">First to offer in Dallas area upon approval</li>
                        <li style="margin-bottom: 10px;">Experienced team ready to prescribe and manage care</li>
                        <li style="margin-bottom: 10px;">Seamless transition for current patients</li>
                        <li>Priority access for waitlist members</li>
                    </ul>
                    <p style="margin-top: 15px; font-weight: 600; color: #2d5a3d;">Join the waitlist to be notified immediately when available.</p>
                </div>
            </div>

            <div style="background: white; border: 2px solid #e8ede6; border-radius: 8px; padding: 25px; margin-top: 30px;">
                <h3 style="color: #2d5a3d; margin-bottom: 15px;">What Happens After FDA Approval?</h3>
                <ol style="padding-left: 20px; line-height: 1.8;">
                    <li style="margin-bottom: 15px;"><strong>FDA Decision:</strong> Regulatory approval expected 2025-2026</li>
                    <li style="margin-bottom: 15px;"><strong>Supply Ramp:</strong> Manufacturer begins distribution to medical providers</li>
                    <li style="margin-bottom: 15px;"><strong>Insurance Processing:</strong> Coverage policies and reimbursement established</li>
                    <li style="margin-bottom: 15px;"><strong>Summer House Launch:</strong> We notify waitlist members and begin offering retatrutide</li>
                    <li><strong>Your Access:</strong> Schedule consultation and begin treatment</li>
                </ol>
            </div>
        </div>
    </section>

    <section class="section" id="current-options">
        <div class="container">
            <h2>Don't Wait — Start Weight Loss Now</h2>

            <p style="text-align: center; margin-bottom: 40px; font-size: 16px; max-width: 800px; margin-left: auto; margin-right: auto;">
                While retatrutide moves through FDA approval, proven weight loss medications are available today at Summer House Aesthetics. Start achieving results now.
            </p>

            <div class="two-column">
                <div class="feature-box">
                    <h4>Semaglutide (Ozempic)</h4>
                    <p style="font-size: 18px; color: #2d5a3d; margin: 12px 0; font-weight: 600;">15-18% Weight Loss</p>
                    <ul style="margin: 15px 0; padding-left: 20px; font-size: 14px;">
                        <li style="margin-bottom: 8px;">FDA approved 2021</li>
                        <li style="margin-bottom: 8px;">GLP-1 agonist</li>
                        <li style="margin-bottom: 8px;">Weekly injection</li>
                        <li>Proven track record with millions</li>
                    </ul>
                    <p style="margin-top: 15px;"><a href="#waitlist" style="color: #2d5a3d; text-decoration: none; font-weight: 600;">Learn more about semaglutide →</a></p>
                </div>

                <div class="feature-box">
                    <h4>Tirzepatide (Mounjaro/Zepbound)</h4>
                    <p style="font-size: 18px; color: #2d5a3d; margin: 12px 0; font-weight: 600;">20-22% Weight Loss</p>
                    <ul style="margin: 15px 0; padding-left: 20px; font-size: 14px;">
                        <li style="margin-bottom: 8px;">FDA approved 2022-2023</li>
                        <li style="margin-bottom: 8px;">GLP-1/GIP dual agonist</li>
                        <li style="margin-bottom: 8px;">Weekly injection</li>
                        <li>Better results than semaglutide</li>
                    </ul>
                    <p style="margin-top: 15px;"><a href="#waitlist" style="color: #2d5a3d; text-decoration: none; font-weight: 600;">Learn more about tirzepatide →</a></p>
                </div>
            </div>

            <div style="text-align: center; margin-top: 40px;">
                <a href="#waitlist" class="cta-button" style="display: inline-block;">Schedule Your Consultation</a>
            </div>
        </div>
    </section>

    <section class="section" id="faq">
        <div class="container">
            <h2>Questions About Retatrutide?</h2>

            <div class="faq-item">
                <div class="faq-question">
                    <span>What exactly is a triple agonist?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>A triple agonist is a medication that activates three different receptors in the body. Retatrutide activates GLP-1, GIP, and glucagon receptors — three separate pathways that all contribute to weight loss. This is more comprehensive than semaglutide (1 pathway) or tirzepatide (2 pathways).</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>Is retatrutide available now?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>No, retatrutide is not yet FDA-approved. It's currently in Phase 3 clinical trials with an expected approval timeline of 2025-2026. Once approved, it will be available through prescription from licensed physicians like those at Summer House Aesthetics.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>Why is 24-26% weight loss so significant?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>Current FDA-approved options show 15-22% weight loss. Retatrutide's 24-26% represents a meaningful improvement — an additional 4-11 percentage points. For someone weighing 200 lbs, this means 48-88 additional pounds of weight loss compared to current options. That difference is clinically significant.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>What about side effects?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>Common side effects are similar to other GLP-1 class medications: nausea, vomiting, diarrhea, and constipation. These are typically mild and transient, decreasing over time as your body adjusts. Serious side effects are rare. A physician consultation will review your individual risk profile.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>How is retatrutide administered?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>Retatrutide is expected to be administered as a once-weekly subcutaneous injection, similar to semaglutide and tirzepatide. You'll receive training on self-injection during your initial consultation, and it takes just minutes to administer at home.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>Will insurance cover retatrutide?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>Insurance coverage will likely follow patterns established for semaglutide and tirzepatide. Most plans require a BMI threshold and documentation of previous weight loss attempts. Summer House can help with insurance verification and prior authorization once retatrutide is available.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>Can I switch from tirzepatide to retatrutide?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>Potentially, yes. Many patients currently on tirzepatide or semaglutide may be candidates to switch to retatrutide once it becomes available. This transition will be individualized based on your response to current treatment and physician assessment.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>Why should I join the waitlist if it's not available yet?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>Joining the waitlist ensures you're notified the moment reatatrutide becomes available in Dallas. You'll have priority access and can schedule a consultation immediately upon approval, rather than waiting weeks or months to learn about it through other sources.</p>
                </div>
            </div>

            <div class="faq-item">
                <div class="faq-question">
                    <span>Should I wait for retatrutide or start treatment now?</span>
                    <span class="faq-toggle">▼</span>
                </div>
                <div class="faq-answer">
                    <p>That's a personal decision based on your timeline and goals. If you want to start losing weight immediately, semaglutide and tirzepatide are proven options available now. If you prefer to wait for potentially superior results, retatrutide will likely be available within 12-18 months. Discuss with our physician to determine what's best for your situation.</p>
                </div>
            </div>
        </div>
    </section>

    <section class="section" id="waitlist">
        <div class="container">
            <h2>Join the Dallas Retatrutide Waitlist</h2>
            <p style="text-align: center; color: #666; margin-bottom: 30px;">
                Be first in Dallas to access retatrutide when FDA approval is complete. Enter your information and we'll notify you immediately upon availability.
            </p>

            <form class="waitlist-form" action="#" method="POST">
                <div class="form-group">
                    <label for="name">Full Name *</label>
                    <input type="text" id="name" name="name" required>
                </div>

                <div class="form-group">
                    <label for="email">Email Address *</label>
                    <input type="email" id="email" name="email" required>
                </div>

                <div class="form-group">
                    <label for="phone">Phone Number (Optional)</label>
                    <input type="tel" id="phone" name="phone">
                </div>

                <div class="form-group">
                    <label>I'm interested in:</label>
                    <div style="margin-top: 10px;">
                        <label style="display: flex; align-items: center; margin-bottom: 8px; font-weight: 400;">
                            <input type="checkbox" name="interested" value="retatrutide" style="margin-right: 10px; width: auto;" checked> Retatrutide (when available)
                        </label>
                        <label style="display: flex; align-items: center; margin-bottom: 8px; font-weight: 400;">
                            <input type="checkbox" name="interested" value="tirzepatide" style="margin-right: 10px; width: auto;"> Tirzepatide now
                        </label>
                        <label style="display: flex; align-items: center; margin-bottom: 8px; font-weight: 400;">
                            <input type="checkbox" name="interested" value="semaglutide" style="margin-right: 10px; width: auto;"> Semaglutide now
                        </label>
                        <label style="display: flex; align-items: center; font-weight: 400;">
                            <input type="checkbox" name="interested" value="consultation" style="margin-right: 10px; width: auto;"> Schedule a consultation
                        </label>
                    </div>
                </div>

                <button type="submit" class="form-submit">Join the Waitlist</button>

                <p style="text-align: center; font-size: 12px; color: #999; margin-top: 15px;">
                    We respect your privacy. We'll only contact you about retatrutide availability.
                </p>
            </form>
        </div>
    </section>

    <footer>
        <div class="container">
            <p><strong>Summer House Aesthetics</strong></p>
            <p>Dallas, Texas</p>
            <p style="margin-top: 20px; font-size: 12px;">
                Retatrutide information is for educational purposes. This page does not provide medical advice.
                Consult with a healthcare provider about whether retatrutide or other weight loss medications
                are appropriate for you. Retatrutide is not yet FDA-approved; availability is subject to regulatory approval.
            </p>
            <p style="margin-top: 15px;">
                <a href="#">About Us</a> | <a href="#">Contact</a> | <a href="#">Privacy Policy</a> | <a href="#">Terms of Service</a>
            </p>
        </div>
    </footer>

    <script>
        // FAQ Toggle Functionality
        const faqItems = document.querySelectorAll('.faq-item');

        faqItems.forEach(item => {
            const question = item.querySelector('.faq-question');
            question.addEventListener('click', () => {
                item.classList.toggle('active');
            });
        });

        // Form Submission
        const form = document.querySelector('.waitlist-form');
        if (form) {
            form.addEventListener('submit', (e) => {
                e.preventDefault();
                alert('Thank you for joining the Dallas retatrutide waitlist! You\'ll be among the first to know when it\'s available at Summer House Aesthetics.');
                form.reset();
            });
        }

        // Smooth scrolling for anchor links
        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function (e) {
                const href = this.getAttribute('href');
                if (href !== '#') {
                    e.preventDefault();
                    const element = document.querySelector(href);
                    if (element) {
                        element.scrollIntoView({ behavior: 'smooth' });
                    }
                }
            });
        });
    </script>
</body>
</html>
